Literature DB >> 25182099

Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011.

Allison W Kurian1, Daphne Y Lichtensztajn2, Theresa H M Keegan3, David O Nelson3, Christina A Clarke3, Scarlett L Gomez3.   

Abstract

IMPORTANCE: Bilateral mastectomy is increasingly used to treat unilateral breast cancer. Because it may have medical and psychosocial complications, a better understanding of its use and outcomes is essential to optimizing cancer care.
OBJECTIVE: To compare use of and mortality after bilateral mastectomy, breast-conserving therapy with radiation, and unilateral mastectomy. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study within the population-based California Cancer Registry; participants were women diagnosed with stages 0-III unilateral breast cancer in California from 1998 through 2011, with median follow-up of 89.1 months. MAIN OUTCOMES AND MEASURES: Factors associated with surgery use (from polytomous logistic regression); overall and breast cancer-specific mortality (from propensity score weighting and Cox proportional hazards analysis).
RESULTS: Among 189,734 patients, the rate of bilateral mastectomy increased from 2.0% (95% CI, 1.7%-2.2%) in 1998 to 12.3% (95% CI, 11.8%-12.9%) in 2011, an annual increase of 14.3% (95% CI, 13.1%-15.5%); among women younger than 40 years, the rate increased from 3.6% (95% CI, 2.3%-5.0%) in 1998 to 33% (95% CI, 29.8%-36.5%) in 2011. Bilateral mastectomy was more often used by non-Hispanic white women, those with private insurance, and those who received care at a National Cancer Institute (NCI)-designated cancer center (8.6% [95% CI, 8.1%-9.2%] among NCI cancer center patients vs 6.0% [95% CI, 5.9%-6.1%] among non-NCI cancer center patients; odds ratio [OR], 1.13 [95% CI, 1.04-1.22]); in contrast, unilateral mastectomy was more often used by racial/ethnic minorities (Filipina, 52.8% [95% CI, 51.6%-54.0%]; OR, 2.00 [95% CI, 1.90-2.11] and Hispanic, 45.6% [95% CI, 45.0%-46.2%]; OR, 1.16 [95% CI, 1.13-1.20] vs non-Hispanic white, 35.2% [95% CI, 34.9%-35.5%]) and those with public/Medicaid insurance (48.4% [95% CI, 47.8%-48.9%]; OR, 1.08 [95% CI, 1.05-1.11] vs private insurance, 36.6% [95% CI, 36.3%-36.8%]). Compared with breast-conserving surgery with radiation (10-year mortality, 16.8% [95% CI, 16.6%-17.1%]), unilateral mastectomy was associated with higher all-cause mortality (hazard ratio [HR], 1.35 [95% CI, 1.32-1.39]; 10-year mortality, 20.1% [95% CI, 19.9%-20.4%]). There was no significant mortality difference compared with bilateral mastectomy (HR, 1.02 [95% CI, 0.94-1.11]; 10-year mortality, 18.8% [95% CI, 18.6%-19.0%]). Propensity analysis showed similar results. CONCLUSIONS AND RELEVANCE: Use of bilateral mastectomy increased significantly throughout California from 1998 through 2011 and was not associated with lower mortality than that achieved with breast-conserving surgery plus radiation. Unilateral mastectomy was associated with higher mortality than were the other 2 surgical options.

Entities:  

Mesh:

Year:  2014        PMID: 25182099      PMCID: PMC5747359          DOI: 10.1001/jama.2014.10707

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   157.335


  36 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

Review 2.  American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology.

Authors:  Lowell E Schnipper; Thomas J Smith; Derek Raghavan; Douglas W Blayney; Patricia A Ganz; Therese Marie Mulvey; Dana S Wollins
Journal:  J Clin Oncol       Date:  2012-04-03       Impact factor: 44.544

3.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

4.  Complications following bilateral prophylactic mastectomy.

Authors:  Mary B Barton; Carmen N West; In-Lu A Liu; Emily L Harris; Sharon J Rolnick; Joann G Elmore; Lisa J Herrinton; Sarah M Greene; Larissa Nekhlyudov; Suzanne W Fletcher; Ann M Geiger
Journal:  J Natl Cancer Inst Monogr       Date:  2005

5.  Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women.

Authors:  Paula J C Bresser; Caroline Seynaeve; Arthur R Van Gool; Cecile T Brekelmans; Hanne Meijers-Heijboer; Albert N van Geel; Marian B Menke-Pluijmers; Hugo J Duivenvoorden; Jan G M Klijn; Aad Tibben
Journal:  Plast Reconstr Surg       Date:  2006-05       Impact factor: 4.730

Review 6.  Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002.

Authors:  Katharine Yao; David J Winchester; Tomasz Czechura; Dezheng Huo
Journal:  Breast Cancer Res Treat       Date:  2013-11-12       Impact factor: 4.872

7.  Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status.

Authors:  E Shelley Hwang; Daphne Y Lichtensztajn; Scarlett Lin Gomez; Barbara Fowble; Christina A Clarke
Journal:  Cancer       Date:  2013-01-28       Impact factor: 6.860

8.  A tutorial on propensity score estimation for multiple treatments using generalized boosted models.

Authors:  Daniel F McCaffrey; Beth Ann Griffin; Daniel Almirall; Mary Ellen Slaughter; Rajeev Ramchand; Lane F Burgette
Journal:  Stat Med       Date:  2013-03-18       Impact factor: 2.373

9.  The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2013-09-30       Impact factor: 2.373

10.  Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research.

Authors:  Allison W Kurian; Aya Mitani; Manisha Desai; Peter P Yu; Tina Seto; Susan C Weber; Cliff Olson; Pragati Kenkare; Scarlett L Gomez; Monique A de Bruin; Kathleen Horst; Jeffrey Belkora; Suepattra G May; Dominick L Frosch; Douglas W Blayney; Harold S Luft; Amar K Das
Journal:  Cancer       Date:  2013-09-24       Impact factor: 6.921

View more
  69 in total

1.  BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.

Authors:  Shoshana M Rosenberg; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Lidia Schapira; Steven Come; Virginia F Borges; Bryce Larsen; Judy E Garber; Ann H Partridge
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

2.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

3.  Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.

Authors:  Jada G Hamilton; Margaux C Genoff; Melissa Salerno; Kimberly Amoroso; Sherry R Boyar; Margaret Sheehan; Megan Harlan Fleischut; Beth Siegel; Angela G Arnold; Erin E Salo-Mullen; Jennifer L Hay; Kenneth Offit; Mark E Robson
Journal:  Breast Cancer Res Treat       Date:  2017-02-01       Impact factor: 4.872

4.  Evaluating a Decision Aid for Improving Decision Making in Patients with Early-stage Breast Cancer.

Authors:  Sarah T Hawley; Lisa Newman; Jennifer J Griggs; Mary Ann Kosir; Steven J Katz
Journal:  Patient       Date:  2016-04       Impact factor: 3.883

Review 5.  Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients.

Authors:  Giacomo Montagna; Monica Morrow
Journal:  Expert Rev Anticancer Ther       Date:  2020-02-28       Impact factor: 4.512

6.  Breast-conserving therapy and modified radical mastectomy for primary breast carcinoma: a matched comparative study.

Authors:  Lize Wang; Tao Ouyang; Tianfeng Wang; Yuntao Xie; Zhaoqing Fan; Benyao Lin; Jinfeng Li
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

7.  Does "Two is Better Than One" Apply to Surgeons? Comparing Single-Surgeon Versus Co-surgeon Bilateral Mastectomies.

Authors:  Melissa Anne Mallory; Katya Losk; Kristen Camuso; Stephanie Caterson; Suniti Nimbkar; Mehra Golshan
Journal:  Ann Surg Oncol       Date:  2015-10-29       Impact factor: 5.344

8.  Factors Affecting Surgical Decisions in Newly Diagnosed Young Women with Early-Stage Breast Cancer.

Authors:  Shoshana M Rosenberg; Mary L Greaney; Andrea F Patenaude; Ann H Partridge
Journal:  J Adolesc Young Adult Oncol       Date:  2019-04-03       Impact factor: 2.223

9.  Contralateral prophylactic mastectomy in young women with breast cancer: a population-based analysis of predictive factors and clinical impact.

Authors:  A Bouchard-Fortier; N N Baxter; R Sutradhar; K Fernandes; X Camacho; P Graham; M L Quan
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

Review 10.  The Right Treatment for the Right Patient - Personalised Treatment of Breast Cancer.

Authors:  A Scharl; T Kühn; T Papathemelis; A Salterberg
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-07       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.